| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.04 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.04 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.04 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.07 | 0.04 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.04 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.06 | 0.04 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.04 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | 0.076 | 0.04 |